Health
Largest pharmacogenetic clinical trial in cardiology shows potential benefit in individualized approach – Mirage News
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement― nonsurgical procedures to improve blood flow to the heart ― are…
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement― nonsurgical procedures to improve blood flow to the heart ― are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke. New research from the international TAILOR-PCI trial, the largest pharmacogenetics clinical trial in cardiology, suggests that genetic testing could potentially be a useful tool to help select antiplatelet medication. Pharmacogenetics is the…
-
Noosa News12 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General16 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General14 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba
-
Business21 hours agoTop brokers name 3 ASX shares to buy next week 5 October 2025